Vyome Holdings (HIND) AI Stock Analysis

• Market Cap: $10.84M
• Dividend Yield: N/A
• Average Volume (3M): 1.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: -48.74%
• EPS Growth: 89.18%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.12
• Shares Outstanding: 5,644,494
• 10 Day Avg. Volume: 4,640,952
• 30 Day Avg. Volume: 1,562,352
• PEG Ratio: 0.01
• Price to Book (P/B): -36.35
• Price to Sales (P/S): 1.15
• P/FCF Ratio: -2.08
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 1.61
• Enterprise Value/Gross Profit: 2.58
• Enterprise Value/Ebitda: -0.49
• 1Y Price Target: $15.00
• Price Target Upside: 176.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.82
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.00 ▼(-63.10% Downside)

The score is held down primarily by deteriorating revenue, very large losses, and ongoing cash burn that increase financing/dilution risk. Technicals also indicate a sustained downtrend. Offsetting factors are modest: low current leverage and positive corporate updates around VT-1953’s perceived market potential, but these do not overcome the weak current financial profile.

Positive Factors

Revenue Growth

Consistent revenue growth indicates improved market penetration and product acceptance, which can enhance long-term financial stability.

Cost Reduction

Significant cost reductions enhance profitability and operational efficiency, providing a stronger foundation for future growth.

Regulatory Approval

Health Canada's approval of Lap-Band 2.0 FLEX expands market opportunities, potentially increasing revenue streams and competitive positioning.

Negative Factors

Financial Distress

Negative equity and financial distress indicate potential solvency issues, threatening long-term viability and financial flexibility.

Cash Flow Challenges

Persistent negative cash flow suggests ongoing operational challenges, limiting the company's ability to invest in growth and innovation.

Competitive Pressure

Intense competition from GLP-1 pharmaceuticals could erode market share and hinder revenue growth, impacting long-term competitiveness.

Vyome Holdings Business Overview & Revenue Model

Company Description

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.

How the Company Makes Money

ReShape Lifesciences generates revenue through the sale of its medical device products, primarily the Lap-Band System, to healthcare providers and medical facilities. The company also offers related accessories and support services, which contribute to its revenue streams. Additionally, ReShape may engage in partnerships with healthcare organizations and leverage its intellectual property to enhance its market presence and financial performance. The company's earnings are influenced by factors such as market demand for obesity treatments, competitive positioning, and regulatory approvals.

Vyome Holdings Financial Statement Overview

Summary

Weak fundamentals dominate: TTM revenue declined sharply (-34.99%) with very large ongoing losses (TTM net margin ~-274%) and persistent cash burn (TTM operating/free cash flow ~-$3.0M; free cash flow growth -61.14%). Low TTM leverage (debt-to-equity ~0.02) is a positive, but balance sheet quality is mixed given negative stockholders’ equity shown in 2024 annual results and historical swings in capital structure.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined sharply (-34.99%), extending a multi-year pattern of contraction after 2021. Gross margins remain solid and stable (~62% TTM), but the company continues to post very large operating and net losses (TTM net margin ~-274%), indicating the cost base is far above current scale. Losses have improved versus the extreme 2021–2022 period, but profitability remains a clear weakness with no near-term inflection visible in the provided results.

Balance Sheet

Leverage is currently low (TTM debt-to-equity ~0.02), which reduces solvency risk and provides some flexibility. However, equity has been volatile—annual 2024 shows negative stockholders’ equity—highlighting balance sheet instability and past losses/financing impacts. Total debt has also swung materially across years, so while today’s leverage looks manageable, the quality and consistency of the capital base remain a key risk.

Cash Flow

Cash burn is persistent: TTM operating and free cash flow are both around -$3.0M, and free cash flow deteriorated versus the prior period (TTM free cash flow growth -61.14%). Cash flow is not supporting earnings (operating cash flow relative to net income is negative in TTM and recent years), and free cash flow remains negative across all periods shown—typical for development-stage biotech, but it heightens dilution/financing risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.19M	8.01M	8.68M	11.24M	13.60M	11.30M
Gross Profit	2.62M	5.06M	5.55M	6.80M	8.35M	6.26M
EBITDA	-13.66M	-6.65M	-11.18M	-44.33M	-60.62M	-18.09M
Net Income	-11.51M	-7.13M	-11.39M	-46.21M	-63.15M	-21.63M
Balance Sheet
Total Assets	7.05M	4.79M	10.73M	11.27M	52.53M	39.71M
Cash, Cash Equivalents and Short-Term Investments	5.71M	693.00K	4.56M	3.96M	22.77M	3.01M
Total Debt	38.61K	967.00K	262.00K	171.00K	279.00K	13.25M
Total Liabilities	3.13M	5.05M	4.06M	7.60M	8.20M	25.23M
Stockholders Equity	2.53M	-253.00K	6.66M	3.66M	44.33M	14.49M
Cash Flow
Free Cash Flow	-2.96M	-4.43M	-17.00M	-22.03M	-15.73M	-8.94M
Operating Cash Flow	-2.96M	-4.43M	-16.96M	-21.90M	-15.38M	-8.55M
Investing Cash Flow	0.00	0.00	-10.00K	-92.00K	1.85M	-2.39M
Financing Cash Flow	8.54M	677.00K	17.57M	3.13M	33.30M	11.07M

Vyome Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIND, the sentiment is Negative. The current price of 5.42 is above the 20-day moving average (MA) of 2.92, above the 50-day MA of 3.84, and below the 200-day MA of 10.77, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 33.38 is Neutral, neither overbought nor oversold. The STOCH value of 8.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIND.

Vyome Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOVE	47 Neutral	$15.58M	-0.65	-398.78%	―	-44.57%	55.97%
HIND	46 Neutral	$10.84M	-0.01	-565.18%	―	-48.74%	89.18%
HSCS	46 Neutral	$10.27M	-0.47	-220.42%	―	-41.03%	35.71%
HSDT	43 Neutral	$113.58M	>-0.01	―	―	87.45%	72.30%
SINT	40 Underperform	$12.36M	-0.46	-204.04%	―	-60.89%	94.49%
VERO	40 Underperform	$2.36M	-0.03	-854.61%	―	-12.39%	44.61%

Vyome Holdings Corporate Events

Vyome Holdings Highlights VT-1953 Market Potential Analysis

On January 27, 2026, Vyome Holdings released new data from an independent U.S. market assessment, commercial forecast and valuation analysis for VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. The study by Destum Partners highlights significant unmet need in this end-of-life oncology complication, identifies an absence of approved or late-stage competing therapies, and positions VT-1953 as a potential first-in-class topical treatment designed to address multiple core symptoms including malodor and pain. Destum’s base-case rNPV analysis values VT-1953 at $455 million in the United States as of Phase 2 completion, with modeled asset value rising to more than $1 billion in 2028 following anticipated Phase 3 completion, and implies a total U.S. addressable pharmacologic market for malignant fungating wound symptom treatment of about $2.2 billion in 2026, growing to $2.8 billion by 2040, underscoring the asset’s potential clinical and commercial importance and the strategic relevance of securing a partner with strong oncology supportive or wound-care capabilities.

The most recent analyst rating on (HIND) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.

Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition

On December 17, 2025, Vyome Holdings, Inc., through its indirect subsidiary LiveChain, Inc. (LICH), entered into a binding letter of intent with Remus Capital Series B II, L.P. to acquire a senior secured convertible note issued by Sociometric Solutions, Inc., d/b/a Humanyze, in exchange for issuing Remus a 25% fully diluted equity stake in LICH immediately prior to closing, with an additional 10% of LICH’s equity reserved for key and future employees, leaving current shareholders with an expected 65% post-closing stake. The transaction, treated as a related party deal and approved by both the company’s Audit Committee and Board after the recusal of Remus-affiliated directors, will be executed through a newly formed LICH subsidiary under a Note Purchase and Exchange Agreement, includes a $20,000 good-faith deposit to Humanyze, grants Remus the right to appoint one LICH director, and is structured to be completed within roughly 75 days of the LOI execution, potentially reshaping LICH’s capital structure and governance while ensuring Humanyze remains active to service select obligations.

The most recent analyst rating on (HIND) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.